Watch FLGT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
48
WATCH · insiders 44, shorts 51
Insiders, 90 days
−$117K
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $542.9MP/E —DIV YIELD —FCF YIELD -19.12%REV TTM $323.9M +6.8%NET INCOME −$84.4MNET CASH —52W 13.79 – 30.85NEXT EARNINGS Nov 6SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $85.4M | +4.4% | 30.1% | −$36.1M | −$29.5M | — | — | −$23.8M | $3.9M | −$27.6M | Jul 30 |
| Q1 2026 · Mar 31 | $71.1M | −3.2% | 30.2% | −$34.6M | −$24.8M | — | — | $7.1M | $5.2M | $1.9M | May 1 |
| Q4 2025 · Dec 31derived | $83.3M | +9.3% | 39.1% | −$36.2M | −$23.4M | — | — | −$78.1M | $5M | −$83.1M | Feb 27 |
| Q3 2025 · Sep 30 | $84.1M | +17.2% | 42.2% | −$15.3M | −$6.6M | — | — | $11.1M | $6M | $5.1M | Nov 7 |
| Q2 2025 · Jun 30 | $81.8M | +15.2% | 42.1% | −$19.7M | −$19M | — | — | −$30.2M | $6.8M | −$37M | Jul 30 |
| Q1 2025 · Mar 31 | $73.5M | +13.9% | 38.6% | −$19.8M | −$11.5M | — | — | −$4.4M | $4.7M | −$9.1M | May 1 |
| Q4 2024 · Dec 31derived | $76.2M | +8.1% | 41.8% | −$16.1M | −$5.9M | — | — | $25M | $3.8M | $21.2M | Feb 27 |
| Q3 2024 · Sep 30 | $71.7M | −15.3% | 37.3% | −$17.1M | −$14.6M | — | — | −$15.5M | $19.5M | −$35M | Nov 7 |
| Q2 2024 · Jun 30 | $71M | — | 37.3% | −$18.9M | −$8.7M | — | — | $4.3M | $12.9M | −$8.7M | Aug 1 |
| Q1 2024 · Mar 31 | $64.5M | — | 34.3% | −$21.8M | −$13.5M | — | — | $7.3M | $4.1M | $3.2M | May 2 |
| Q4 2023 · Dec 31derived | $70.5M | — | 35.8% | −$151.1M | −$128.1M | — | — | $14.9M | $3.1M | $11.8M | Feb 27 |
| Q3 2023 · Sep 30 | $84.7M | — | 47.0% | $214K | −$13.1M | — | — | $10.2M | $4.9M | $5.3M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $322.7M | 40.6% | −$91.1M | −$60.5M | -18.8% | — | −$101.6M | $22.6M | −$124.2M | $10.9M | — |
| FY2024 · to Dec 31 | $283.5M | 37.8% | −$73.9M | −$42.7M | -15.1% | — | $21.1M | $40.3M | −$19.3M | $225K | — |
| FY2023 · to Dec 31 | $289.2M | 36.1% | −$195.5M | −$167.8M | -58.0% | — | $27M | $22.2M | $4.8M | $25.1M | — |
| FY2022 · to Dec 31 | $619M | 59.3% | $178.5M | $143.4M | 23.2% | — | $253.5M | $18.8M | $234.7M | $74.3M | — |
| FY2021 · to Dec 31 | $992.6M | 78.3% | $676M | $507.4M | 51.1% | — | $538.6M | $23.8M | $514.8M | — | — |
| FY2020 · to Dec 31 | $421.7M | 78.7% | $290.2M | $214.3M | 50.8% | — | $140.6M | $35.1M | $105.5M | $62K | — |
Every number comes from Fulgent Genetics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.